Thursday, January 23, 2014
Publication and contact
Programmed cell death 1 (PDCD1;
PD-1; CD279); hepatitis
A virus cellular receptor 2 (HAVCR2;
suggest combining antibodies against PD-1 and TIM3 could increase patient
response to melanoma vaccines. In peripheral blood mononuclear cells (PBMCs)
taken from patients with metastatic melanoma vaccinated with tumor-associated
antigen 1B (CTAG1B;
peptide, antigen-specific T cell expression of PD-1 and TIM3 was upregulated
in about 73% and 18% of cases. In the PBMCs, the NY-ESO-1 peptide plus both
anti-PD-1 and anti-TIM3 antibodies showed an additive effect in expanding
tumor antigen-specific T cells. Next steps could include testing the antibody
combination with cancer vaccines in patients.
Squibb Co. and Ono
Pharmaceutical Co. Ltd. have the PD-1 antibody nivolumab
in Phase III trials to treat melanoma.
& Co. Inc. has the PD-1 antibody lambrolizumab
in Phase III testing for the indication.
At least four other companies have antibodies against PD-1 in Phase II or
earlier testing to treat cancers.
Published online Jan. 23, 2014
Patent and licensing status
Fourcade, J. et al.
published online Dec. 16, 2013;
Contact: Hassane M. Zarour, University of Pittsburgh School
of Medicine, Pittsburgh, Pa.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]